Respublikanskaya klinicheskaya bol'nica imeni N.A.Semashko
Ankylosing spondylitis causes morphological or functional damage to the cardiovascular system in 22% of cases. Using modern methods of heart function research, such as Holter ECG monitoring, it is possible to detect rhythm and conduction disorders, long QT syndrome. Changes in the parameters of the QT interval, such as its duration and variance, can be considered as a predictor of the development of cardiovascular catastrophes and fatal arrhythmias. The article analyzes the values of QT/RR and QTc during Holter ECG monitoring in 92 patients diagnosed with Ankylosing spondylitis, depending on the stage of the disease, the activity of the pathological process, and seropositivity for HLA B27. There was a significant increase in QT/RR and QTc during the active and passive periods of Holter ECG monitoring in comparison with the control group. In patients with ankylosing spondylitis, ventricular arrhythmias were detected, which are associated with prolongation of the QT interval. Standardized Holter ECG monitoring in patients with Ankylosing spondylitis, taking into account the daily variance of the QT interval, can become a universal, minimally invasive and low-cost method for assessing the risk of cardiovascular disorders in patients with Ankylosing spondylitis.
ankylosing spondylitis, QT interval, Holter ECG monitoring
1. Buber J., Mathew J., Moss A. J. Risk of recurrent cardiac events after onset of menopause in women with congenital long QT syndrome types 1 and 2. Circulation. 2011; 123(24):2784-2791.
2. Hinterseer M., Beckmann B. M., Thomsen M. B., Pfeufer A., Dalla Pozza R., Loeff M. Relation of increased short-term variability of QT interval to congenital long-QT syndrome. Am. J. Cardiol.2009;103(9):1244-1248.
3. Wu G., Ai T., Kim J.J. Alpha-1-syntrophin mutation and the long QT syndrome: A disease of sodium channel disruption. Circ. Arrythm. Electrophysiol. 2008;1 (3):193-201.
4. Goldenberg I., Moss A.J., Peterson D.R., McNitt S., Zareba W., Andrews M.L. Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation. 2008;17(17):2184-2191.
5. Goldenberg I., Moss A.J. Long QT syndrome. JACC. 2008;51(24):2291-2300.
6. Tayzhanova D. Zh., Romanyuk Yu. L. Sindrom udlinennogo intervala QT: voprosy diagnostiki i lecheniya. Mezhdunarodnyy zhurnal prikladnyh i fundamental'nyh issledovaniy. 2015;(2):218-221.
7. Ichkhan K., Molnar J., Somberg J. Relation of left ventricular mass and QT dispersion in patients with systematic hypertension. Am. J. Cardiol. 1997;79:508- 511.
8. Heart rate-corrected QT interval duration is significantly associated with blood pressure in Chinese hypertensives/S. Peng, Y. Yu, K. Hao J. Electrocardiol. 2006;39(2):206-210.
9. Revishvili A. Sh., Neminuschiy N. M., Batalov R. E. Vserossiyskie klinicheskie rekomendacii po kontrolyu nad riskom vnezapnoy ostanovki serdca i vnezapnoy serdechnoy smerti, profilaktike i okazaniyu pervoy pomoschi. Vestnik aritmologii.2017;89:2-104.
10. Ziegler D., Zentai C. P., Perz S. Prediction of mortality using measures of cardiac autonomic disfunction in diabetic and nondiabetic population: MONICA/KORA Augsburg cohort study. Diabet. Care. 2008; 31(3):556-561.
11. Dimitropoulos G., Tahrani A. A., Stevens M. J. Cardiac autonomic neuropathy in patients with diabetes mellitus. World J Diabetes. 2014;5(1):17-39. doi:https://doi.org/10.4239/wjd.v5.i1.17.
12. Vinik A.I., Maser R. E., Mitchell B. D., Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003;26(6):1553-1579. doihttps://doi.org/10.2337/diacare.26.6.1895
13. Beom J. W., Kim J. M., Chung E. J. Corrected QT interval prolongation during severe hypoglycemia without hypokalemia in patients with type 2 diabetes. Diabet. Metab. J. 2013;37(3):190-195
14. Christensen T. F., Cichosz S. L., Tarnow L. Hypoglycaemia and QT interval prolongation in type 1 diabetes-bridging the gap between clamp studies and spontaneous episodes. J. Diabet. Complications. 2014;28(5):723-728.
15. Nguyen L., Su S., Nguyen H. T. Effects of hyperglycemia on variability of RR, QT and corrected QT intervals in type 1 diabetic patients. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2013;1819-1822
16. Han C., Robinson D. W. Jr., Hackett M.V. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33(11):2167-72.
17. Roldan C. A., Chavez J., Wiest P. W. Aortic root disease associated with ankylosing spondylitis. J Am Col Cardiol 1998;32(5):1397-404.
18. Godzenko A., Korsakova Y., Bochkova A. Progression of aortic and valve abnormalities in patients with ankylosing spondylitis. Annual European Congress of Rheumatology EULAR; 2016, Abstracts. AB0666.
19. Klingberg E., Svealv B., Tang M. Aortic regurgitation is common in ankylosing spondylitis: Time for routine echocardiography evaluation? Am J Med. 2015 Nov;128(11):1244-50.doi:10.1016/ j.amjmed.2015.04.032.Epub 2015 Jun 4.
20. Heslinga S. C. High Prevalence of Cardiac Disease in Patients with Ankylosing Spondylitis 2015 ACR\ARHR Annual Meeting. September 29,2015.
21. Bergfeldt L. HLA-B27-associated Cardiac Disease. Ann Intern Med.1997;127(8 Pt 1):621-629.
22. Van der Linden S., Valkenburg H., Cats A. Evaluation of diagnosticcriteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361-8.doi:10.1002/ art.1780270401
23. Zochling J., van der Heijde D., Burgos- Vargas R. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2006;65:442-52. doihttps://doi.org/10.1136/ard.2005.04113715.
24. Heart rate variability. Standart of measurement, physiological, and clinical use. Task Force of European Society of Cardiology and The North American Society of Pacing and electrophysiology. Europ.Heart J. 1996;17:354-381.
25. Holter N. J. New method for heart studies: continuous electrocardiography of active subects over long periods is now practical. Science. 1961;134:1214- 1220.
26. Straus S. M., Sturkenboom M. C., Bleumink G. S. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. .Eur. Heart J. 2005;26:2007- 2012.
